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Abstract
Background: Assessment of diffuse right ventricular (RV) fibrosis is of particular interest in pulmonary hypertension
(PH) and heart failure (HF). Current cardiovascular magnetic resonance (CMR) T1 mapping techniques such as Modified
Look-Locker inversion recovery (MOLLI) imaging have limited resolution, but accelerated and navigator-gated
Look-Locker imaging for cardiac T1 estimation (ANGIE) is a novel CMR sequence with spatial resolution
suitable for T1 mapping of the RV. We tested the hypothesis that patients with PH would have significantly
more RV fibrosis detected with MRI ANGIE compared with normal volunteers and patients having HF with reduced (LV)
ejection fraction (HFrEF) without co-existing PH, independent of RV dilatation and dysfunction.
Methods: Patients with World Health Organization group 1 or group 4 PH, patients with HFrEF without PH, and
normal volunteers were recruited to undergo contrast-enhanced CMR. RV and LV extracellular volume fractions
(RV-ECV and LV-ECV) were determined using pre-contrast and post-contrast T1 mapping using ANGIE (RV and LV)
and MOLLI (LV only).
Results: Thirty-two participants (53.1 % female, median age 52 years, IQR 26–65 years) were enrolled, including n = 12
with PH, n = 10 having HFrEF without co-existing PH, and n = 10 normal volunteers. ANGIE ECV imaging was of high
quality, and ANGIE measurements of LV-ECV were highly correlated with those of MOLLI (r = 0.91; p < 0.001). The
RV-ECV in PH patients was 27.2 % greater than the RV-ECV in normal volunteers (0.341 v. 0.268; p < 0.0001) and 18.9 %
greater than the RV-ECV in HFrEF patients without PH (0.341 v. 0.287; p< 0.0001). RV-ECV was greater than LV-ECV in
PH (RV-LV difference = 0.04), but RV-ECV was nearly equivalent to LV-ECV in normal volunteers (RV-LV difference = 0.002)
(p < 0.0001 for RV-LV difference in PH versus normal volunteers). RV-ECV was linearly associated with both increasing
RVEDVI (p = 0.049) and decreasing RVEF (p = 0.04) in a multivariable linear model, but PH was still associated with greater
RV-ECV even after adjustment for RVEDVI and RVEF.
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Conclusions: Pre- and post-contrast ANGIE imaging provides high-resolution ECV determination for the RV. PH is
independently associated with increased RV-ECV even after adjustment for RV dilatation and dysfunction, consistent
with an independent effect of PH on fibrosis. ANGIE RV imaging merits further clinical evaluation in PH.
Keywords: Magnetic resonance, Pulmonary hypertension, Fibrosis, T1 mapping, Extracellular volume fraction, Right
ventricle
Background
Right ventricular (RV) dysfunction in pulmonary hyper-
tension (PH) is not only an indicator of severity of dis-
ease but also a cause of heart failure (HF) [1, 2] and the
most important predictor of survival [3–6]. RV patho-
physiology in PH and HF involves complex interactions
among myocardial injury, altered gene expression, ven-
tricular remodeling, the renin-angiotensin-aldosterone
system, natriuretic peptides, the endothelin system, and
various cytokines, leading to fibrosis, cell death, myocar-
dial dysfunction, and reduced systemic perfusion [7–9].
Left ventricular (LV) fibrosis is of considerable interest
and readily evaluated in hypertension and other cardio-
vascular diseases [10], while RV fibrosis is more difficult
to assess than LV fibrosis because of the specific attri-
butes of RV anatomy, including the thin RV free wall,
differences in structure between the septum and free
wall, and the complex 3D structure including an outflow
tract. Although echocardiography provides some infor-
mation on RV structure and function [11], cardiovascu-
lar magnetic resonance (CMR) is generally considered
the gold standard in this regard, even though CMR as-
sessment of fibrosis in PH has been limited to evaluation
of scar by late gadolinium enhancement (LGE) at LV
septal insertion sites [12, 13]. Consequently, the strength
of CMR for the RV has traditionally been high-definition
cine imaging with a steady-state free precession protocol
rather than contrast-enhanced fibrosis imaging.
There is a growing literature for T1 mapping of the LV,
and the myocardial extracellular volume (ECV) fraction
determined with this technique has been shown to correl-
ate with histologic fibrosis [14–22]; however, current T1
mapping methods have insufficient spatial resolution for
effective RV fibrosis imaging [14]. For example, limitations
of common T1 mapping methods such as modified Look-
Locker inversion recovery imaging (MOLLI) [14] include
suboptimal spatial resolution and the need for breath
holding during scanning. In response, our group has
developed a method for high quality CMR T1 map-
ping of the RV called accelerated and navigator-gated
Look-Locker imaging for cardiac T1 estimation (ANGIE)
[20], which employs navigator gating and compressed
sensing to provide a 4-fold improvement in spatial reso-
lution compared with MOLLI without the need for a
breath hold.
Considering that we have previously demonstrated
the accuracy of ANGIE for native T1 mapping of the
LV and RV [20], the aim of the present study was to
demonstrate the feasibility and effectiveness of contrast-
enhanced ANGIE imaging for determination of RV-ECV
and LV-ECV in a cross-sectional study composed of a)
patients with World Health Organization (WHO) groups
1 or 4 PH (without LV systolic dysfunction), b) pa-
tients having HF with reduced (LV) ejection fraction
(LVEF) (HFrEF) without co-existing PH, and c) nor-
mal volunteers. Because the RV in PH is compro-
mised by high pressures, which lead to chamber
dilatation, dysfunction, and fibrosis, we hypothesized
that patients with PH would have significantly more RV
fibrosis detected with ANGIE compared with normal vol-
unteers and patients having HF with reduced (LV) ejection




All participants provided written informed consent, and
the study was conducted according to standard ethical
principles, as documented in the study protocol ap-
proved by our Institutional Review Board for Human
Subjects Research. Patients were recruited to undergo
CMR with a gadolinium-based contrast agent. The study
population was divided into three groups of subjects. The
PH cohort (n = 12) consisted of patients diagnosed with
PH classified as WHO group 1 (pulmonary arterial hyper-
tension) or 4 (chronic thromboembolic PH). WHO groups
1 and 4 were chosen for the PH cohort rather than WHO
groups 2 (PH due to left heart diseases), 3 (PH due to lung
diseases and/or hypoxemia), or 5 (PH with unclear multi-
factorial mechanisms) in order to provide a PH cohort
with preserved LV systolic function without extensive
comorbid cardiopulmonary disease. The second group
consisted of patients with HFrEF without PH (n = 10).
The third group (n = 10) consisted of healthy volun-
teers who served as the control group for this study.
Patients were excluded from the study if they had
standard contraindications for gadolinium-enhanced
CMR. All patients were required to have a glomerular
filtration rate (GFR) of at least 45 cc/minute/1.73 m2 (cal-
culated based on a serum creatinine drawn within 30 days
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of the CMR study using the Modification of Diet in
Renal Disease [MDRD] equation). Although we did
not enroll patients on intravenous prostacyclin, these
patients could be included in future studies, but
would require nursing assistance with the tubing ex-
tension to maintain a connection with the pump dur-
ing the scan.
CMR protocol and image reconstruction
All CMR studies were performed using a 1.5 T MRI
scanner (Avanto, Siemens, Erlangen, Germany). Peri-
pheral intravenous access was obtained, and the he-
matocrit was determined from a peripheral blood
draw for the calculation of ECV, as described in more
detail below. After electrocardiography leads were
placed, each patient was positioned in the magnet. A
5-channel phased-array radiofrequency coil was used
for signal reception. With respect to the CMR im-
aging protocol for this study, a standard localizer was
first performed to identify the cardiac short- and
long-axis planes. Steady-state free precession cine im-
ages were then obtained for assessment of the RV
end-diastolic volume index (RVEDVI), the LV end-
diastolic volume index (LVEDVI), RV end-systolic vol-
ume index (RVESVI), LV end-systolic volume index
(LVESVI), RVEF, and LVEF. Specific parameters in-
cluded: TR = 2.7 ms, TE = 1.3 ms, flip angle = 70°,
FOV = 300–350 mm, and in-plane spatial resolution =
1.8 × 1.4 mm2. The entire heart was covered using a
stack of short-axis slices with a thickness of 8 mm
and an inter-slice gap of 2 mm. Three long-axis slices
were also acquired in two-chamber, three-chamber,
and four-chamber views.
Next, pre-contrast ANGIE T1 mapping was per-
formed. For ANGIE, two mid-ventricular short-axis
slices were imaged at end systole to maximize RV
wall thickness and separation of the RV wall from the
liver and the chest wall during imaging. The mid-
ventricular short-axis slices were aligned perpendicular
to the major-axis of the RV and positioned in a region
with minimal variation along the through plane direc-
tion in order to minimize the partial volume effects.
The ANGIE protocol utilized repetitions of an inver-
sion pulse followed by four consecutive ECG-triggered
data acquisitions and a recovery period of two R-R in-
tervals, as well as the following sequence parameters:
TR = 3.2 ms, TE = 1.6 ms, flip angle = 35°, FOV =
270–340 mm, matrix size = 224 × 224, in-plane reso-
lution = 1.2–1.4 × 1.2–1.4 mm2, slice thickness = 4 mm,
acquisition window duration = 102 ms per heartbeat,
phase encodes per heartbeat = 32, navigator acceptance
window = ± 3 mm, initial inversion time = 160 ms,
inversion time increment = 80 ms, and acceleration
rate = 2. For all ANGIE scans, the raw k-space data
were exported from the scanner, and image recon-
struction was performed offline on a personal computer
as previously described [20].
Following pre-contrast ANGIE, gadolinium-DTPA
(Magnevist, Bayer Healthcare) was injected intraven-
ously with a dose of 0.15 mmol/kg. LGE CMR was
performed 10 min following gadolinium-DTPA injec-
tion at slice locations matching those acquired using
cine CMR. A phase sensitive inversion recovery se-
quence was used with the inversion time set to null
normal appearing myocardium. Specific sequence param-
eters included TR = 3.2 ms, TE = 1.6 ms, flip angle = 25°,
FOV = 300–340 mm, resolution = 1.8 × 1.3 mm2, and
slice thickness = 4 mm. The image acquisition was
timed to occur at end systole for alignment with T1
mapping acquisitions. Post-contrast ANGIE T1 map-
ping acquisitions were performed at 20 min and 30 min
after contrast administration using the same parameters
and slice locations as the pre-contrast ANGIE T1 map-
ping acquisitions.
Modified Look-Locker inversion recovery (MOLLI)
T1 mapping scans were also performed both pre- and
post-contrast in PH patients for validation of ANGIE
LV-ECV measurements. For both pre- and post-
contrast imaging, we used a shorter variant of MOLLI
(MOLLI 5-(R4)-3) comprised of two inversion recov-
ery based Look-Locker experiments [23]. The shorter
MOLLI sequence acquired 5 images after the first
inversion, used a four heart-beat pause, and then
acquired three images after the second inversion. The
slice locations matched those of the ANGIE acquisi-
tion, and the image acquisition was timed to occur at
end systole for alignment with the ANGIE T1 maps.
Specific imaging parameters for MOLLI were TR =
2.7 ms, TE = 1.16 ms, FOV = 300–310 mm, matrix
size = 192 × 154, pixel size = 1.6–1.7 × 1.9–2.1 mm2,
flip angle = 35°, slice thickness = 4 mm, acquisition
window duration = 234 ms per heartbeat, initial TI =
100 ms, and TI increment = 80 ms. Only LV-ECV was
determined with MOLLI because MOLLI did not pro-
vide sufficient resolution for a meaningful determin-
ation of RV-ECV. In contrast, ANGIE provided sufficient
resolution for the RV [Fig. 1].
CMR data analysis and ECV determination
Myocardial borders were manually delineated on steady
state free precession cine images using Argus software
(Siemens Medical Solutions, Munich, Germany) for de-
termination of RVEDVI, LVEDVI, RVEF, and LVEF. All
other image analysis was performed using custom soft-
ware developed in MATLAB (The Mathworks, Inc.,
Natick, Massachusetts).
For ANGIE and MOLLI, T1 maps were computed
as described previously [20]. Manual contours for the
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RV and LV were drawn in a conservative manner on
images at one inversion time to exclude trabecula-
tions. Non-scar regions of myocardium were identified for
analysis of ECV by the absence of enhancement in
the corresponding LGE image. The myocardial parti-
tion coefficient for gadolinium-DTPA (λGd) was com-
puted from the myocardial and the LV blood T1
estimates using the standard equation [23–25]:
λGd ¼ Gd concentration in myocardiumGd concentration in blood
¼ 1=T 1 myo with Gd−1=T 1 myo without Gd
1=T 1 blood with Gd−1=T 1 blood without Gd
Myocardial ECV was calculated from λGd and the
blood hematocrit using the established relationship:
ECV = λGd(1 − hematocrit) [23–25].
Assessment of PH with echocardiography and right heart
catheterization
Evaluation for the presence of PH in both groups
of patients was assessed based on right heart
catheterization and echocardiography results. The
result obtained from the right heart catheterization
was considered the gold standard. RV systolic pres-
sures by echocardiography were assessed based on the
peak tricuspid regurgitation jet velocity and right atrial
pressure using the standard calculation based on the
simplified Bernoulli equation.
Statistical analysis
All statistical analyses were performed using SAS 9.4
(Carey, North Carolina) and SigmaPlot 12.5 (Systat
Software, Inc., San Jose, California). Continuous vari-
ables were described using the median and interquartile
range. The distribution of the continuous variables be-
tween groups was assessed using the Shapiro-Wilk test
for normality. For selected variables with a confirmed
normal distribution, the mean was also used. Compari-
sons of continuous variables between groups were per-
formed using the Kruskal-Wallis test. Categorical values
were described using frequencies and percentages in the
different groups, and comparisons between groups were
performed using Fisher’s exact test. Correlations between
continuous variables were assessed using Pearson’s cor-
relation coefficient after confirmation of normality and
evaluated with scatter plots. Multivariable linear regres-
sion was used to assess the complex relationship be-
tween RV-ECV, RVEF, and RVEDVI, and the underlying
clinical condition.
Interobserver variability was assessed for RV-ECV,
pre-contrast T1, and post-contrast T1 in 10 randomly
selected participants. The intraclass correlation coeffi-
cient (ICC) is reported as the primary measure of inter-
observer variability.
Results
Patient cohort and baseline CMR parameters
Thirty-two participants were enrolled in the study
(53.1 % female, median age 52 years old, IQR 26–65
years old). Patient characteristics for the entire cohort
are described in Table 1. Of note, 75 % of PH patients
were on advanced therapies for PH, including 50 % on
an endothelin receptor antagonist (ERA), 58.3 % on sil-
denafil, and 16.7 % on a prostacyclin analog.
CMR parameters for PH patients, HFrEF patients,
and healthy volunteers are shown in Table 2, which
shows that RVEF was decreased, and both RVEDVI
and RVESVI were increased in PH compared with
HFrEF and normal volunteers (p < 0.05 for all). Specif-
ically, RVEF was most significantly depressed in the
PH group (34.0 % [IQR 30.5–42.5 %]), mild-moder-
ately depressed in the HFrEF group (41.0 % [IQR
38.0–48.0 %], and normal in volunteers (55.5 % [IQR
52.0–58.2 %]). In HFrEF patients, LVEF was decreased
(p < 0.0001), and LVEDVI (p = 0.0001), LVESVI (p =
0.001), and LVMI (p = 0.008) were increased compared
with PH patients and normal volunteers.
Right heart catheterization was used for the diagnosis
of PH. Patients with HFrEF had no evidence of PH by
Fig. 1 Examples of ANGIE T1 maps for PH and HFrEF. ANGIE T1
maps before and after injection of gadolinium in patients with heart
failure with reduced ejection fraction (HFrEF) (a, b) and pulmonary
hypertension (PH) (c, d) show excellent definition of the right
ventricular (RV) free wall
Mehta et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:110 Page 4 of 11
Doppler echocardiography. RV systolic pressure was
twofold higher in the PH cohort compared with the
HFrEF cohort by Doppler echocardiography (52.3 mm
Hg versus 26.8 mm Hg; p = 0.01).
ECV mapping results
Examples of high-resolution pre- and post-contrast
ANGIE T1 maps of the LV and RV acquired from HFrEF
(a-b) and PH (c-d) patients are shown in Fig. 1. These
examples illustrate the high quality of ANGIE T1 maps
for this cohort of patients. The ANGIE T1 maps in both
patients show good definition of not only the LV but
also the RV. Figure 2 illustrates determination of the RV
(A and C) and LV (B and D) myocardial partition coeffi-
cients for gadolinium-DTPA (λGd) using T1 estimates of
the myocardium and LV blood pool.
Correlation of ANGIE and MOLLI LV- ECV assessments
MOLLI acquisitions were obtained in addition to
ANGIE in patients with PH (n = 12). The distribution of
LV-ECV in these patients was determined to be normal.
As shown in Fig. 3, the ANGIE measurements of LV-
ECV in PH patients were highly correlated with MOLLI
measurements (r = 0.91; p < 0.001), which supports the
accuracy of myocardial ECV measurement using ANGIE
T1 mapping.
Table 1 Baseline characteristics
PH (N = 12) HFrEF (N = 10) Normal (N = 10) p-value
Age (years [IQR]) 64.5 (47.5–70.5) 60.0 (53.0–65.0) 24.4 (21.7–26.3 <0.001
Gender (% female) 8 (66.7) 1 (10.0) 8 (80.0) 0.004
BMI (kg/m2 [IQR]) 25.4 (23.0–29.3) 29.2 (26.0–32.7) 24.1 (21.2–26.3) 0.47
Ischemic HD (%) 1 (8.3) 8 (80.0) 0 (0.0) <0.0001
Congenital HD (%) 1a (8.3) 1 (10.0) 0 (0.0) 1.0
DM (%) 2 (16.7) 3 (30.0) 0 (0.0) 0.23
OSA (%) 3 (25.0) 2 (20.0) 0 (0.0) 0.33
HIV (%) 2 (16.7) 0 (0.0) 0 (0.0) 0.31
CTEPH (%) 2 (16.7) 0 (0.0) 0 (0.0) 0.31
Medication-ERA 6 (50.0) 0 (0.0) 0 (0.0) 0.002
Medication-sildenafil 7 (58.3) 0 (0.0) 0 (0.0) 0.0003
Medication-PA 2 (16.7) 0 (0.0) 0 (0.0) 0.31
Continuous variable are reported as median (IQR)
CTEPH chronic thromboembolic pulmonary hypertension, DM diabetes mellitus, ERA endothelin receptor antagonist, HD heart disease, HIV human
immunodeficiency virus, OSA obstructive sleep apnea, PA prostacyclin analogue, TE thromboembolism
aThis patient has severe pulmonary hypertension resulting from late repair of a ventricular septal defect
Table 2 CMR parameters
PH (N = 12) HFrEF (N = 10) Normal (N = 10) p value
RVEF (%) 34.0 (30.5–42.5) 41.0 (38.0–48.0) 55.5 (52.0–58.0) 0.001
RVEDVI (ml/m2) 87.9 (75.0–119.2) 59.0 (50.4–67.9) 60.8 (59.0-70.1) 0.02
RVESVI (ml/m2) 59.1 (47.7–80.9) 35.0 (23.0–37.4) 29.8 (26.8-32.4) 0.007
RV T1 pre-contrast (ms) 1056 (1021–1081) 1003 (922–1029) 974 (927–996) 0.005
RV T1 post-contrast (ms) 482 (428–509) 480 (449–506) 514 (503–538) 0.05
RV-ECV 0.343 (0.331-0.352) 0.294 (0.272-0.301) 0.270 (0.251-0.281) <0.0001
LVEF (%) 55.0 (50.0–58.5) 28.0 (19.0–31.0) 61.2 (59.7–62.9) <0.0001
LVEDVI (ml/m2) 58.2 (43.1–66.1) 109.0 (102.9–124.8) 84.3 (80.3–90.3) 0.0001
LVESVI (ml/m2) 28.2 (21.2–41.6) 62.3 (45.5–79.6) 32.7 (29.9–37.4) 0.001
LVMI (g/m2) 36.9 (32.7–41.0) 61.1 (50.7–70.5) 32.3 (30.1-35.8) 0.008
LV T1 pre-contrast (ms) 988 (963–1006) 969 (921–988) 971 (948–986) 0.40
LV T1 post-contrast (ms) 495 (438–542) 480 (454–505) 519 (491–546) 0.28
LV-ECV 0.305 (0.295-0.308) 0.276 (0.258-0.290) 0.271 (0.251-0.279) 0.002
Results are shown as the median (IQR)
ECV extracellular volume fraction, LV left ventricle, LVEDVI left ventricular end-diastolic volume index, LVEF left ventricular ejection fraction, LVESVI left ventricular
end-systolic volume index, RV right ventricle, RVEDVI right ventricular end-diastolic volume index, RVEF right ventricular ejection fraction, RVESVI right ventricular
end-systolic volume index
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Comparison of RV-ECV in PH, HFrEF, and normal volunteers
Figure 4a summarizes the ranges for RV-ECV among
patients with PH, HFrEF, and normal volunteers. The
RV-ECV in PH patients was 27.2 % greater than the
RV-ECV in normal volunteers (0.341 v. 0.268;
p < 0.0001) and 18.9 % greater than the RV-ECV in
HFrEF patients (0.341 v. 0.287; p < 0.0001). RV-ECV
was greater than LV-ECV in PH (RV-LV difference =
0.04), but RV-ECV was nearly equivalent to LV-ECV
in normal volunteers (RV-LV difference = 0.002) (p <
0.0001 for RV-LV difference in PH versus normal
volunteers).
Independence of RV-ECV from RVEF and detection of
occult RV fibrosis
In all study participants from all groups, greater RV-
ECV by ANGIE was associated with decreasing
RVEF by CMR (r = −0.75, p = 0.001). In Fig. 5, pa-
tients were grouped into three RVEF groups and
three RV-ECV groups. A normal RV-ECV was de-
fined as less than 28.7 % based on the RV-ECV value
at the 99th percentile for RV-ECV in the 10 normal
volunteers (range 0.249–0.287). Normal LV-ECV
values have also been published for patients with T1
mapping in 1.5 T and 3.0 T magnets [26, 27]; however,
we used data from our normal volunteers for the normal
RV-ECV values, which are not well-established in the lit-
erature. Among the 22 patients in the PH and HFrEF
groups, forty-three percent of patients with a normal
RVEF had an abnormal RV-ECV (ECV Group 2), indicat-
ing a significant prevalence of occult fibrosis despite a nor-
mal RVEF. In patients with mildly depressed RVEF,
50 % of the patients had an elevated RV-ECV (ECV
Group 2). In patients with a moderately-severely
depressed RVEF, there was a range of abnormal ECV,
with 43 % having a modest increase in RV-ECV (ECV
Group 2), and 57 % having a more severe increase in
RV-ECV. These ranges demonstrate that patients with
similar degrees of RV dysfunction by RVEF can have
variable RV-ECV values (ECV group 3). In fact, RV-
ECV ranged from 0.25−0.37 in patients with an abnor-
mal RVEF.
Multivariable model: RV-ECV, RVEF, and RV end-diastolic
volume
Figure 6 summarizes the complex relationship between
RV-ECV, RVEDVI, and RVEF. The multivariable linear
model with these variables is described in more detail in
Table 3. Both decreasing RVEF and increasing RVEDVI
were independently associated with increasing RV-ECV
in these patients. Even after adjustment for RVEF and
RVEDVI, the clinical diagnostic group (PH v. HFrEF
v. Normal) was still independently associated with
RV-ECV. The overall R2 for this model was 0.804
(adjusted R2 = 0.783; p < 0.0001). The independent as-
sociation of RV-ECV with the diagnostic group even
Fig. 2 Myocardial partition coefficients for gadolinium-DTPA (λGadolinium) in patients with PH and HFrEF. Results for the right ventricular (RV) and
left ventricular (LV) λGadolinium are shown for patients with heart failure with reduced ejection fraction (HFrEF) (a, b) and pulmonary hypertension
(PH) (c, d). λGadolinium is estimated as the slope of the linear fit of 1/(myocardial T1) vs 1/ (LV blood pool T1) measured at various time
points pre- and post-injection of gadolinium-DTPA
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after adjustment for RVEF and RVEDVI suggests the
presence of independent factors associated with PH rela-
tive to other groups that lead to increased ECV independ-
ent of the degree of RV dilatation or dysfunction.
Interobserver variability
We also assessed interobserver variability for RV-ECV
and RV T1 values before and after contrast in 10 ran-
domly selected participants with contrast-enhanced
MRIs in the PH and HFrEF groups. We found that
the ICC for RV-ECV was 0.851, the ICC for the RV
pre-contrast T1 value was 0.945, and the ICC for the
RV post-contrast T1 value was 0.798.
Discussion
This is the first report of T1 and ECV determination for
the RV in a clinical population of patients with PH or
HFrEF without PH. There were several key clinical
findings of particular importance to the field of CMR,
T1 mapping, RV imaging, ECV determination, and
PH. First, ANGIE ECV assessment for the RV is feas-
ible in these patient groups and generates high- reso-
lution results for both the RV and the LV. Second,
Fig. 4 ECV results in PH, HFrEF, and normal volunteers. a Box plots are
shown for these three groups of patients. RV-ECV is higher in PH versus v
HFrEF (p< 0.0001), in PH versus normal volunteers (p< 0.0001), and in
HFrEF versus normal volunteers (p= 0.049). b Box plots are shown for
the differences in RV-ECV and LV-ECV in these three groups of patients.
The difference between RV-ECV and LV-ECV is greater in PH versus HFrEF
(p< 0.0006) and greater in PH versus normal volunteers (p< 0.0001). The
RV-LV ECV difference in HFrEF versus normal volunteers did not meet
statistical significance (p= 0.15)
Fig. 5 Relationship between RV systolic dysfunction and RV-ECV.
Right ventricular ejection fraction (RVEF) and RV extracellular volume
fraction (RV-ECV) are each divided into three groups, and the distribution
of RV-ECV for different RVEF groups is shown. There is a significant
correlation between RVEF and RV-ECV (r = −0.75; p = 0.001)
Fig. 3 Validation of the accuracy of ECV measurements using ANGIE
T1 mapping. a This panel shows the correlation plot comparing left
ventricular extracellular volume (LV-ECV) in pulmonary hypertension
(PH) obtained with accelerated and navigator-gated Look-Locker
imaging for cardiac T1 estimation (ANGIE) versus the modified
Look-Locker inversion recovery (MOLLI) imaging. The ANGIE
measurements of LV-ECV (in regions excluding scar on late gadolinium
enhancement) in PH patients were in close agreement with
those of MOLLI (r = 0.91; p < 0.001), confirming the accuracy of
ECV measurements performed using ANGIE. b The corresponding
Bland-Altman plot is shown. SD = standard deviation
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ANGIE measurements of LV-ECV correlated well with
MOLLI measurements of LV-ECV. Although MOLLI
measurements of RV T1 values were of insufficient
resolution to permit comparison with the higher reso-
lution ANGIE T1 and ECV measurements, the strong
correlation between MOLLI and ANGIE for LV-ECV
is very important because it shows for the first time
that ECV values of the LV as measured with ANGIE are
comparable to those determined with MOLLI imaging.
The third significant finding is that ANGIE detected
significantly higher RV-ECV values in PH patients com-
pared with normal volunteers and patients with HFrEF
without PH. Of note, although RV involvement in
HFrEF is not uncommon, particularly those with PH,
the patients we chose for the HFrEF cohort did not have
PH. In addition, the measures of RV size and function
were closer to those of normal volunteers in patients
with HFrEF compared with the corresponding measures
in patients in the PH group. In particular, RVEDVI was
reduced by more than 30 % in HFrEF, while RVESVI
was reduced by more than 40 % in HFrEF compared
with PH.
A fourth significant finding is that RV-ECV repre-
sents a unique parameter describing RV structure that
is associated with RVEF and RVEDVI but is not
merely a surrogate for one of these parameters. This
was shown by the results of the multivariable linear
model with RV-ECV as the outcome variable. In this
model, RV-ECV was independently associated with both
RVEF and RVEDVI modeled as independent variables.
Furthermore, the clinical diagnostic group was also highly
associated with RV-ECV even after adjustment for RVEF
and RVEDVI. This is consistent with independent biologic
factors in PH that result in greater RV-ECV in PH com-
pared with patients having HFrEF and normal volunteers,
independent of the degree of RV dysfunction and
dilatation.
Imaging of fibrosis and scar in the RV in pulmonary
hypertension
The findings justify further study regarding the use of
this RV fibrosis imaging technique in patients with
PH [3–6]. While noninvasive imaging methods have
shown several measurable indices to be reliable surro-
gates for RV function (such as RV strain [11]), there
has not been an effective way to image diffuse RV
fibrosis prior to the present study. While the use of
LGE can be used to localize focal fibrosis [12, 28], its
Fig. 6 3D depiction of relationships among RV Fibrosis, dysfunction, and dilatation. The 3D surface plot shows the complex relationships among
RV-ECV, RVEF, and RVEDVI. Please also refer to Table 3, which shows that patient group, RVEDVI, and RVEF are independently associated
with RV-ECV. The surface is highest in the corner corresponding to decreased RVEF and increased RVEDVI
Table 3 Multivariable model for RV-ECV
Variable DF Parameter estimate Standard error t value p value
Intercept 1 0.361 0.0182 19.8 <.0001
RVEF 1 −0.000829 0.000360 −2.3 0.03
RVEDVI 1 0.000296 0.000128 2.32 0.03
Diagnostic group 1 −0.0234 0.00563 −4.16 0.0003
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use in patients with PH has been limited to imaging
of LV septal fibrosis at the RV insertion points [29,
30]. Although it is clear that fibrosis is important in
the RV in PH, traditional imaging of scar with LGE
in the RV free wall is technically difficult. Further-
more, while T1 mapping protocols such as MOLLI
have been used to quantify the myocardial ECV in
the LV, their use in the RV has been limited because
of inadequate spatial resolution.
ANGIE as a solution to the inherent challenges of RV T1
mapping
ANGIE presents a unique solution to T1 mapping of
the thin RV free wall. Just as we showed the high qual-
ity of native ANGIE imaging of the RV in a recent pub-
lication [20], the high quality of post-contrast ANGIE
T1 mapping of the RV is shown in Fig. 1. This high
resolution is achieved by several innovative imaging
techniques, described previously. Briefly, ANGIE em-
ploys navigator gating to allow acquisition of images
during free breathing and, consequently, to achieve
higher spatial resolution. To do so in a reasonable scan
time, ANGIE also uses compressed sensing and parallel
imaging for acceleration. These innovations provide
high resolution imaging of the thin-walled RV in a very
acceptable period of imaging time. ANGIE results for
both the RV and LV can be obtained during a single
study and using the same contrast injection used for
LGE imaging of the LV, also performed during the
study. As described in the methods, one pre-contrast
native ANGIE acquisition and two post-LGE ANGIE ac-
quisitions are typically performed. Analysis of RV-ECV
was found to be very reproducible. The ICC of 0.945 for
interobserver agreement for pre-contrast RV T1 values
was also quite high and consistent with values obtained in
volunteers in our previously published study using this
technique [20]. The ICC for post-contrast RV T1 values
was also very good but slightly lower than that for the RV
pre-contrast T1 values.
Clinical applications and significance
There are a number of potential clinical applications of
RV fibrosis assessment in patients with PH and others
with HFrEF. First, RV-ECV could be used for risk strati-
fication of patients with PH in combination with RVEF,
if additional follow-up data confirm that RV-ECV, like
RVEF, is associated with adverse clinical outcomes.
Second, RV-ECV assessment could be used to monitor
the effectiveness of various therapies [31–33] for PH by
performing longitudinal CMR assessments with RV-
ECV measurements. Third, RV-ECV assessment could
be used in animal models of PH in the context of
drug development to compare how novel therapeutic
agents modify the effect of PH on RV fibrosis. Fourth,
RV-ECV mapping could be used to evaluate RV re-
serve in patients being evaluated for cardiac surgery,
pulmonary endartectomy, or lung transplantation, as
early postoperative right ventricular failure is a signifi-
cant cause of morbidity and mortality in these
patients.
Limitations
While the sample size of the present study is adequate
to assess the feasibility and high quality of this method
for RV-ECV determination, as well associations between
RV-ECV and other patient findings, future studies with
ANGIE in PH to evaluate associations with clinical
events are indicated but would require a larger number
of patients. We also acknowledge that fat suppression
could be a potential contaminant of RV T1 and ECV
measurements. Of note, we used fat suppression for the
purpose of limiting partial volume contamination by fat;
however, ANGIE images can be acquired without fat
suppression. Although MRI ECV measurements have
been found to correlate with histologic fibrosis, and we
interpreted elevated ECV in this study as a surrogate for
fibrosis, inflammation and edema may also contribute to
an increased ECV. There were differences in gender in
the groups, but both the PH and volunteer group were
similar in the sense that both had more females than
males. Volunteers were younger than PH and HFrEF pa-
tients, but it has recently been demonstrated that age
does not have a significant effect on CMR measure-
ments of ECV [34]. Another limitation is that ANGIE
was applied to only two slices. To overcome the latter
limitation, we are developing 3D ANGIE methods for
whole heart coverage and more efficient RV imaging
in the future [35].
Conclusions
Pre- and post-contrast ANGIE imaging provides high-
resolution T1 mapping and ECV assessments for not
only the LV but also the RV, with LV-ECV by ANGIE
and MOLLI in close agreement. Elevated RV-ECV in
PH is independently associated not only with RV
chamber dilatation and dysfunction, but also with the
clinical diagnostic group, suggesting that increased
RV-ECV/RV fibrosis in PH results from biologic
factors that cannot be predicted by volumetric RV
findings on CMR. This highlights the importance of
assessing RV-ECV in addition to RV volumes and EF
in PH and other conditions that may adversely affect
the RV. Further studies of RV-ECV in PH and HFrEF
are indicated to assess associations among RV-ECV,
functional limitations, and long-term clinical out-
comes, as well as the effects of drug therapy for PH
on RV-ECV.
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